| A Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALL (NCT00384228) | Novartis Pharmaceuticals | 2005-05-01 |
| Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) (NCT00171899) | Novartis Pharmaceuticals | 2005-04-01 |
| Autologous Transplantation for Chronic Myelogenous Leukemia (NCT01003054) | M.D. Anderson Cancer Center | 2005-03-01 |
| Unrelated Donor Stem Cell Transplantation (NCT01364363) | Scripps Health | 2005-03-01 |
| Study of Dasatinib (BMS-354825) in Patients With Accelerated Phase Chronic Myeloid Leukemia (NCT00101647) | Bristol-Myers Squibb | 2004-12-01 |
| Pilot Study of Reduced-Intensity Umbilical Cord Blood Transplantation in Adult Patients Wtih Advanced Hematopoietic Malignancies (NCT00513318) | University of California, San Francisco | 2004-08-01 |
| PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP (NCT00088231) | M.D. Anderson Cancer Center | 2004-07-01 |
| Infusion of Specially Treated Umbilical Cord Stem Cells After Chemoradiation Treatment for Blood Cancers (NCT00089596) | ViaCell | 2004-03-01 |
| Imatinib (Gleevec(Registered Trademark)) to Treat Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous Leukemia (NCT00079313) | National Heart, Lung, and Blood Institute (NHLBI) | 2004-01-14 |
| Open Label Phase II Study of BAY 43-9006 in Chronic Myelogenous Leukemia (CML) Patients Resistant to Gleevec (NCT00661180) | Bayer | 2004-01-01 |
| A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies (NCT02829775) | Hoffmann-La Roche | 2004-01-01 |
| Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation (NCT00144677) | Dana-Farber Cancer Institute | 2003-11-01 |
| Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (NCT00081926) | Novartis Pharmaceuticals | 2003-10-01 |
| Study of Lonafarnib and Gleevec in Chronic Myelogenous Leukemia (NCT00047502) | M.D. Anderson Cancer Center | 2002-11-01 |
| Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies (NCT00514722) | University of California, San Francisco | 2002-10-01 |
| Investigation of Clofarabine in Acute Leukemias (NCT00098033) | University of Texas | 2002-09-01 |
| Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec) (NCT00042003) | Astex Pharmaceuticals, Inc. | 2002-07-01 |
| Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Chronic Phase Who Are Refractory to Imatinib Mesylate (Gleevec) (NCT00042016) | Astex Pharmaceuticals, Inc. | 2002-07-01 |
| Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Accelerated Phase Who Are Refractory to Imatinib Mesylate (Gleevec) (NCT00041990) | Astex Pharmaceuticals, Inc. | 2002-07-01 |
| T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies (NCT00683046) | University of Chicago | 2001-11-01 |
| Nonmyeloablative Allogeneic Transplant (NCT01272817) | Scripps Health | 2001-10-01 |
| The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen (NCT01890486) | Wake Forest University Health Sciences | 2001-05-21 |
| CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell Transplantation (NCT00038818) | M.D. Anderson Cancer Center | 2001-05-01 |
| Therapy of Relapsed AML With Chemotherapy and Dendritic Cell Activated Lymphocytes (NCT00038870) | M.D. Anderson Cancer Center | 2001-01-31 |
| Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant (NCT00571662) | University of Nebraska | 2000-12-08 |
| Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (NCT00333840) | Novartis Pharmaceuticals | 2000-06-01 |
| T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts (NCT00368355) | Baylor College of Medicine | 2000-04-01 |
| Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies (NCT01499147) | University of Illinois at Chicago | 2000-02-01 |
| Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow (NCT00003838) | National Heart, Lung, and Blood Institute (NHLBI) | 1999-04-15 |
| Polyethylene Glycol Interferon Alfa-2b (PEG Intron) Versus Interferon Alfa-2b (INTRON^® A) in the Treatment of Newly Diagnosed Chronic Myelogenous Leukemia (CML) (C98026) (NCT03547154) | Merck Sharp & Dohme LLC | 1998-10-22 |
| Analysis of Genetic Factors Related to Predisposition and Prognosis of Hematological Malignancies in Israel (NCT00159003) | Deborah Rund | 1998-01-01 |
| Peripheral Blood (PB) Versus Bone Marrow (BM) in Allogeneic Stem Cell Transplantation (NCT01020175) | European Society for Blood and Marrow Transplantation | 1995-01-01 |